J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...

We recently published a list of 11 Best Innovative Stocks to Buy According to Analysts. In this article, we are going to take ...

Franklin Resources trimmed its Pfizer stake by a smidge, selling just 25,315 shares—but when you’ve got over 16 million, ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Potato producer Lamb Weston Holdings Inc., telecom giant Verizon Communications Inc. and retailer TJX Cos. all bucked a sharp market selloff Thursday, as Wall Street turned to stocks offering exposure ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Pfizer (PFE – Research Report), with a price target ...

StoneX Group clearly didn’t skip leg day—it just bulked up its Pfizer holdings by a massive 43.5% in Q4, scooping up over ...

IDEAYA Biosciences, Inc.’s IDYA share price has surged by 10.70%, which has investors questioning if this is right time to sell.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...